6-丁氧基-7H-嘌呤-2-胺 | 76412-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 6-丁氧基-7H-嘌呤-2-胺
• 英文名称: NU2052
• 英文别名: 6-butoxy-7(9)H-purin-2-ylamine；2-Amino-6-butoxy-9H-purine；6-butoxy-9H-purin-2-amine；6-butoxy-7H-purin-2-amine
• CAS: 76412-62-9
• 化学式: C₉H₁₃N₅O
• 分子量: 207.235
• InChiKey: SPHOZXNZJHRHSL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  89.7
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  6-丁氧基-7H-嘌呤-2-胺 在 氢氧化钾 、 三(3,6-二氧杂庚基)胺 、 sodium methylate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 0.83h， 生成 O(6)-正丁基-2'-脱氧鸟苷
  参考文献：
  名称：

  N 7-（2-脱氧-β-D-赤型-戊呋喃糖基）鸟嘌呤（N 7 G d）的碱基配对性能研究†

  摘要：

  研究了N 7-（2-脱氧-β-D-赤型戊呋喃糖基）鸟嘌呤（N 7 G d；1）的碱基配对性质。通过核苷碱基阴离子糖基化获得核苷1。研究了各种6-烷氧基嘌呤-2-胺3a - i与2-脱氧-3,5-二-O-（4-甲苯甲酰基）-α-D-赤型-戊呋喃糖酰氯的糖基化反应（8）。所述Ñ 9 / Ñ 7 -glycosylation比率被发现是1：1时6- isopropoxypurin -2-胺（3D），而6-（2-甲氧基乙氧基）嘌呤-2-亚胺（3i）主要产生N 9-核苷（2：1）。通过固相合成制备含有化合物1的寡核苷酸，并将其与具有四个与N 7 G d相对的常规核苷的互补链杂交。根据双链形成的T m值和焓数据，提出了N 7 G d和dG之间的碱基对。从可能的N 7 G d dG碱基对动机出发，Hoogsteen配对可以被排除，因为7-脱氮基2'-脱氧鸟苷与N 7 G d形成与dG相同的稳定碱基对。

  DOI：

  10.1002/hlca.19970800424
• 作为产物：
  描述：

  2-氨基-6-氯嘌呤 、 正丁醇 在 sodium 作用下， 以54%的产率得到6-丁氧基-7H-嘌呤-2-胺
  参考文献：
  名称：

  Resistance-Modifying Agents. 8. Inhibition of O⁶-Alkylguanine-DNA Alkyltransferase by O⁶-Alkenyl-, O⁶-Cycloalkenyl-, and O⁶-(2-Oxoalkyl)guanines and Potentiation of Temozolomide Cytotoxicity in Vitro by O⁶-(1-Cyclopentenylmethyl)guanine

  摘要：

  A series of O-6-allyl- and O-6-(2-oxoalkyl)guanines were synthesized and evaluated, in comp ari son with the corresponding O-6-alkylguanines, as potential inhibitors of the DNA-repair protein O-6-alkylguanine-DNA alkyltransferase (AGT). Simple O-6-alkyl- and O-6-cycloalkylguanines were weak AGT inactivators compared with O-6-allylguanine (IC50 = 8.5 +/- 0.6 muM) With IC50 values ranging from 100 to 1000 muM. The introduction of substituents at C-2 of the allyl group of O-6-allylguanine reduced activity compared with the parent compound, while analogous compounds in the O-6-(2-oxoalkyl)guanine series exhibited very poor activity (150-1000 muM) O-6-Cycloalkenylguanines proved to be excellent AGT inactivators, with 1-cyclobutenylmethylguanine (IC50 = 0.55 +/- 0.02 muM) and 1-cyclopentenylmethylguanine (IC50 = 0.39 +/- 0.04 muM) exhibiting potency approaching that of the benchmark AGT inhibitor O-6-benzylguanine (IC50 = 0.18 +/- 0.02 muM). 1-Cyclopentenylmethylguanine also inactivated AGT in intact HT29 human colorectal carcinoma cells (IC50 = 0.20 +/- 0.07 muM) and potentiated the cytotoxicity of the monomethylating antitumor agent Temozolomide by approximately 3- and 10-fold, respectively, in the HT29 and Colo205 tumor cell lines. The observation that four mutant AGT enzymes resistant to O-6-benzylguanine also proved strongly cross-resistant to 1-cyclopentenylmethylguanine indicates that the O-6-substituent of each compound makes similar binding interactions within the active site of AGT.

  DOI：

  10.1021/jm000961o

文献信息

• Preparation process of an antiviral drug and intermediates thereof
  申请人：Esteve Química, S.A.

  公开号：EP2474548A1

  公开（公告）日：2012-07-11

  Preparation process of an antiviral drug and intermediates thereof It comprises a preparation process of entecavir comprising: submitting a (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCl or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2-amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.

  抗病毒药物及其中间体的制备过程 本发明涉及一种恩替卡韦的制备过程，包括：将(1S,3R)-3-(叔丁基二甲基硅氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇(VIII)进行双重酯化反应和自由基环化反应，得到公式(V)的化合物，其中化合物(VIII)先进行第一次酯化反应，然后使用二氯化钛作为催化剂，在Mn/2,4,6-共咪唑盐酸盐或Zn/2,4,6-共咪唑/三甲基氯硅烷的存在下进行催化自由基环化反应，最后进行第二次酯化反应；或者，另一种方法是将化合物(VIII)先进行催化自由基环化反应，然后进行酯化反应。恩替卡韦可以通过将化合物(V)进行去硅反应去除TBS基团，然后与2-氨基-6-氯鸟嘌呤进行Mitsunobu偶联反应，再经水解反应制得。本发明还涉及该过程中的一些新型中间体。
• [EN] PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN MÉDICAMENT ANTIVIRAL (ENTÉCAVIR) ET SES INTERMÉDIAIRES
  申请人：ESTEVE QUIMICA SA

  公开号：WO2012085209A1

  公开（公告）日：2012-06-28

  It comprises a preparation process of entecavir comprising: submitting a (1S, 3R)-3-(tert-butyldimethylsilyloxy)-1 -(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCI or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2- amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.

  它包括一种恩替卡韦的制备过程，包括：将(1S, 3R)-3-(叔丁基二甲基硅氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇(VIII)提交给双酯化和自由基环化，得到化合物的公式(V)，其中化合物的公式(VIII)被提交给第一酯化反应，然后在Mn/2,4,6-哥林丁盐酸盐或Zn/2,4,6-哥林丁/三甲基氯硅烷的存在下，使用二氯化钛作为催化剂进行催化自由基环化，最后进行第二酯化反应；或者，化合物的公式(VIII)首先被提交给催化自由基环化，然后进行酯化反应。恩替卡韦可以通过将化合物(V)提交给去硅反应以去除TBS基团，然后与2-氨基-6-氯鸟嘌呤进行三宅信夫偶联，随后进行水解来获得。它还涉及该过程的一些新中间体。
• ENTECAVIR SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF
  申请人：Zheng Zhiguo

  公开号：US20130217879A1

  公开（公告）日：2013-08-22

  The present invention relates to a preparation method for a medicine and an intermediate compound thereof, specifically, relates to a preparation method for entecavir, an intermediate compound thereof, and a synthesis method for the intermediate compound.

  本发明涉及一种药物及其中间体的制备方法，具体涉及恩替卡韦及其中间体的制备方法以及中间体的合成方法。
• [EN] NOVEL INTERMEDIATE AND PROCESS FOR PREPARING ENTECAVIR USING SAME<br/>[FR] NOUVEL INTERMÉDIAIRE ET PROCÉDÉ DE PRÉPARATION D'ENTÉCAVIR L'UTILISANT
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2010074534A2

  公开（公告）日：2010-07-01

  The present invention relates to a novel, high-yield and low-cost method for preparing entecavir, [1-S-(1α,3α,4,β]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one, an antiviral agent, and novel intermediates used therein.

  本发明涉及一种新颖、高产、低成本的恩替卡韦制备方法，[1-S-(1α,3α,4,β]-2-氨基-1,9-二氢-9-[4-羟基-3-(羟甲基)-2-亚甲基环戊基]-6H-嘌呤-6-酮，一种抗病毒药物，以及其中使用的新型中间体。
• PREPARATION PROCESS OF AN ANTIVIRAL DRUG (ENTECAVIR) AND INTERMEDIATES THEREOF
  申请人：Bartra Sanmartí Martí

  公开号：US20130296558A1

  公开（公告）日：2013-11-07

  It comprises a preparation process of entecavir comprising: submitting a (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (VIII) to a double esterification and to a radicalary cyclization, yielding a compound of formula (V), where either a compound of formula (VIII) is submitted to a first esterification reaction, then to a catalytic radicalary cyclization using titanocene dichloride as catalyst in the presence of Mn/2,4,6-collidine HCl or Zn/2,4,6-collidine/trimethylsilyl chloride, and finally to a second esterification reaction or, alternatively, the compound of formula (VIII) is submitted first to a catalytic radicalary cyclization, and then to an esterification reaction. Entecavir can be obtained by submitting compound (V) to a desilylation reaction to remove the TBS group and then to a Mitsunobu coupling with 2-amino-6-chloroguanine, followed by hydrolysis. It also relates to some new intermediates of the process.

  它包括恩替卡韦的制备过程，其中包括：将(1S,3R)-3-(叔丁基二甲基硅氧基)-1-(环氧丙烷-2-基)戊-4-炔-1-醇（VIII）经过双酯化和自由基环化，产生化合物的公式（V）。其中，化合物的公式（VIII）可先经过第一酯化反应，然后在Mn/2,4,6-哌啶盐酸盐或Zn/2,4,6-哌啶/三甲基氯硅烷的存在下，使用二氯化钛作为催化剂进行催化自由基环化，最后再进行第二酯化反应；或者，化合物的公式（VIII）可先进行催化自由基环化，然后再进行酯化反应。将化合物（V）经过去除TBS基团的脱硅反应，然后与2-氨基-6-氯鸟嘌呤进行Mitsunobu偶联，随后进行水解反应，即可得到恩替卡韦。该过程还涉及一些新的中间体。

表征谱图